Search company, investor...

Stage

Other Investors | Alive

About Newport Imaging

Newport Imaging Corporation is working on digital imaging solutions for consumer products. Newport's technology will fundamentally alter the way the company capture and view digital media, enabling new classes of Audio/Visual products. Newport also aims to enable the integration of its scalable platform in both wireless and wired applications.

Headquarters Location

Suite 102

Newport Beach, California, 92663,

United States

Loading...

Loading...

Newport Imaging Patents

Newport Imaging has filed 246 patents.

The 3 most popular patent topics include:

  • semiconductor device fabrication
  • cooking appliances
  • microwave technology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/2/2018

11/28/2023

Microtechnology, Semiconductor device fabrication, Lithography (microfabrication), Nanotechnology, Etching (microfabrication)

Grant

Application Date

9/2/2018

Grant Date

11/28/2023

Title

Related Topics

Microtechnology, Semiconductor device fabrication, Lithography (microfabrication), Nanotechnology, Etching (microfabrication)

Status

Grant

Newport Imaging Frequently Asked Questions (FAQ)

  • Where is Newport Imaging's headquarters?

    Newport Imaging's headquarters is located at Suite 102, Newport Beach.

  • What is Newport Imaging's latest funding round?

    Newport Imaging's latest funding round is Other Investors.

  • Who are the investors of Newport Imaging?

    Investors of Newport Imaging include Palomar Ventures.

  • Who are Newport Imaging's competitors?

    Competitors of Newport Imaging include InVisage Technologies and 6 more.

Loading...

Compare Newport Imaging to Competitors

G
Guidedwave

Guidedwave develops ultrasonic guided wave innovations technology solutions. It offers technology transfer and product development efforts for non-destructive evaluation (NDE) and structural health monitoring (SHM) in the pipeline, rail, aviation, power generation, manufacturing, civil infrastructure, and military products. The company was founded in 1986 and is based in Bellefonte, Pennsylvania.

PhotoShelter Logo
PhotoShelter

PhotoShelter provides portfolio websites, photo sales, and archives tools for photographers. It allows photographers to create a website, or customize it to power existing photography websites. It was founded in 2005 and is based in New York, New York.

I
Industrial Networking Solutions

Industrial Networking Solutions (INS) is a reseller offering a wide range of wired and wireless products for the Internet of Things (“IoT”) market and related engineering and provisioning services. It offers technical support and provides IT services for wired and wireless machine networking applications. Industrial Networking Solutions was founded in 1998 and is based in Richardson, Texas.

S
Subchem Systems

Subchem Systems is a company that received a Department of Defense SBIR/STTR grant for a project entitled: Compact, Lightweight Chemical Sensor for Underwater Explosive Ordnance (EOD) Application. The abstract given for this project is as follows: SubChem Systems Inc. has been involved in the further development, deployment and commercialization of autonomous in-situ chemical analyzers and custom engineered payloads since 1996. SubChem Analyzers have been deployed on commercial AUVs, coastal gliders, autonomous moored vertical profilers, fixed moored structures and other ocean observation platforms. The overall objective of this funding will be to provide a conceptual design of a Diver held chemical sensor capable of sensing chemical/explosive signatures focusing on nitro-based explosives. The requirements needed of the sensor for integration to the DHINS, HULS and BULS systems will also be documented. SubChem Systems maintains the expertise to provide an assessment of several chemical sensing techniques which may be applicable to the sensing of explosives underwater to be applied to the conceptual design. SubChem is currently developing a Miniature Chemical Sensor, ChemFIN, for the detection of trace levels of explosives and other target chemicals. This sensor couples a unique micro-fluidic technology providing a low cost, low power, and platform independent architecture. Funding from this Phase 1 effort will produce a conceptual adaptation to a Diver Held ChemFIN. This variant will incorporate an applicable sensing technology for localization and classification of nitrate-based (TNT,DNT) and potentially peroxide-based (TATP,HMTD) chemical/explosive mixtures.

Z
Zymera Corporation

Zymera Corporation is a company that received a STTR Phase I grant for a project entitled: Non-Toxic Nanoparticles for BRET-Based Molecular Imaging. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will result in the demonstration of non-toxic multi-modality nanoparticle-based molecular probes for in vivo imaging. The objective of the Phase I project is to demonstrate the synthesis and coating of luminescent bismuth sulfide nanoparticles emitting in the near infrared (NIR) for use as multi-modality probes. These probes may be detected by NIR fluorescence emission or as self-illuminated probes through Bioluminescence Resonance Energy Transfer to Luminescent Nanocrystals (BRET-LN). Moreover, bismuth sulfide can be used as a contrast agent for X-ray-based imaging. The presence of toxic metals such as Cd, As, In and Hg in most of the NIR emissive nanoparticles and the relative lack of detailed safety data establish a significant safety barrier for use in humans. Bismuth sulfide is a potentially non-toxic material for bioimaging. Bismuth compounds have been used in pharmaceutical formulations for more than a century to treat maladies such as diarrhea, syphilis, and peptic ulcers. In the U.S., approximately 500 tons of bismuth are used in chemical, cosmetic, and medical products with direct human experience each year. The broader impacts of this research are the development of a sensitive multi-functional molecular imaging probe for use in medical imaging and inter-operative staining procedures. The new probe will ultimately provide a more efficient means to image disease in humans optically, circumventing inherent imaging depth and signal-to-noise limitations of other optical imaging technologies. This capability will translate to the development of important applications such as early cancer detection. Zymera Corporation is a company that received a SBIR Phase I grant for a project entitled: Bioluminescence Resonance Energy Transfer Probes for Molecular Imaging. Their project will demonstrate the detection of an established target in cancer diagnosis and treatment using new targeted Bioluminescence Resonance Energy Transfer to Quantum Dots (BRET-QD) technology. BRET-QD offers substantial advantages over fluorescence or luminescence imaging by: (1), circumventing the need for external illumination while delivering comparable or better sensitivity; (2), providing compatibility with existing image capturing technology; (3), providing superior probe stability compared to radiolabel technology, enabling longitudinal studies; and (4), delivering greater in vivo penetration-depth than fluorescence-based probes. The project will demonstrate the direct detection of the HER2 cancer marker in breast cancer cell lines. Successful detection of HER2 in live cells from a breast cancer cell line will provide the proof-of-concept necessary for advancing to direct tumor and tissue imaging with BRET-QD probes in small animals. The broader impacts of this research are the development of a sensitive and convenient targeted imaging probe platform and its application to breast cancer detection. In order to understand the molecular mechanisms underlying diseases such as cancer, there is increasing interest in advancing from cell-based assays to in vivo imaging of disease states in small animal models. The targeted BRET-QD platform will provide a cost-effective, convenient and effective alternative to fluorescence and bioluminescence imaging probe technology. In addition to cancer applications, this platform will be applicable to virtually any investigation requiring sensitive detection of a known molecule that can be targeted via a biotinylated antibody or other biotinylated molecule. Zymera Corporation is a company that received a SBIR Phase I grant for a project entitled: Bioluminescence Resonance Energy Transfer Assays for Clinical Chemistry. Their research project aims to develop a point-of-care assay for creatine kinase, an important toxicity biomarker, to screen for adverse drug reactions (ADRs) using whole blood. The assay will utilize bioluminescent resonance energy transfer (BRET) probes incorporating quantum dots. The proposed technology is likely to impact toxicity testing, allowing physicians to test for potential ADR at an early stage and take corrective measures. With over 50% of Medicare patients taking multiple medications, the probability of ADRs is high and any inexpensive and reliable test for toxicity would be of benefit to these individuals and society as a whole.

A
Adelphi Technology

Adelphi Technology develops neutron generators and neutron optics. The company offers neutron generators, including deuterium-deuterium (DD) and deuterium-tritium (DT) models, for applications such as materials analysis, nondestructive testing, and security. Adelphi Technology's products are utilized across various fields, including healthcare, security, and education, for research and industrial purposes. It was founded in 1986 and is based in Redwood City, California.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.